Skip to main content
SpringerLink
Log in

SCOUT shows sibutramine not suited to those with CV risks

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL, SCOUT Investigators.Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine 363: 905-917, No. 10, 2 Sep 2010

  2. Curfman GS, Morrissey S, Drazen JM.Sibutramine - another flawed diet pill. New England Journal of Medicine 363: 972-974, No. 10, 2 Sep 2010

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

SCOUT shows sibutramine not suited to those with CV risks. React. Wkly. 1318, 3 (2010). https://doi.org/10.2165/00128415-201013180-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013180-00006

Keywords

Search

Navigation